Literature DB >> 16113360

Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation.

A Hogan1, U Behan, D J Kilmartin.   

Abstract

AIM: To report the visual and angiographic outcomes after combination photodynamic therapy (PDT) and immunosuppression for inflammatory subfoveal choroidal neovascularisation (CNV).
METHODS: Retrospective review of six consecutive patients, five female and one male, aged 23-40 years with active subfoveal CNV secondary to posterior uveitis. Patients received either intravitreal triamcinolone or systemic immunosuppression (mycophenolate mofetil, tacrolimus) and PDT. Five patients had intravitreal triamcinolone injections and two patients were on systemic immunosuppression; all patients underwent PDT (mean two treatments). Visual acuity was measured on a 2 metre ETDRS chart and fluorescein angiograms were performed at each visit.
RESULTS: Median follow up was 15 months (range 10-31). Vision improved by a median of 13 letters in five patients and remained stable (+/-1 letter) in one patient. Median visual acuity improved from 20/160 at presentation to 20/40 at latest follow up (p=0.03). There was a reduction in clinical exudation and cessation of angiographic leakage in all six patients. All interventions were well tolerated.
CONCLUSION: Combination PDT and immunosuppression may be a useful therapeutic option for young patients with active inflammatory subfoveal CNV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113360      PMCID: PMC1772837          DOI: 10.1136/bjo.2004.063024

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

1.  Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome.

Authors:  Ehud Rechtman; Valerie D Allen; Ronald P Danis; Linda M Pratt; Alon Harris; Matthew A Speicher
Journal:  Am J Ophthalmol       Date:  2003-10       Impact factor: 5.258

2.  Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases.

Authors:  Joachim Wachtlin; Heinrich Heimann; Tim Behme; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-11       Impact factor: 3.117

3.  Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration.

Authors:  E Rechtman; R P Danis; L M Pratt; A Harris
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

4.  Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Results of a randomized clinical trial. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1987-11

5.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

6.  IL-10 contributes to the inhibition of contact hypersensitivity in mice treated with photodynamic therapy.

Authors:  G O Simkin; J S Tao; J G Levy; D W Hunt
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

7.  Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults.

Authors:  Adam H Rogers; Jay S Duker; Neil Nichols; Brad J Baker
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

8.  Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study.

Authors:  Philip J Rosenfeld; David A Saperstein; Neil M Bressler; Troy A Reaves; Michel Sickenberg; Robert H Rosa; Paul Sternberg; Thomas M Aaberg; Thomas M Aaberg
Journal:  Ophthalmology       Date:  2004-09       Impact factor: 12.079

9.  Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy.

Authors:  Richard F Spaide; K Bailey Freund; Jason Slakter; John Sorenson; Lawrence A Yannuzzi; Yale Fisher
Journal:  Retina       Date:  2002-10       Impact factor: 4.256

10.  Punctate inner choroidopathy.

Authors:  R C Watzke; A J Packer; J C Folk; W E Benson; D Burgess; R R Ober
Journal:  Am J Ophthalmol       Date:  1984-11       Impact factor: 5.258

View more
  12 in total

1.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Javier A Montero; Jose M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

Review 2.  Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment.

Authors:  Narendra Dhingra; Susan Kelly; Mohammed A Majid; Claire B Bailey; Andrew D Dick
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

3.  Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease.

Authors:  S R Nowilaty; M Bouhaimed
Journal:  Br J Ophthalmol       Date:  2006-05-10       Impact factor: 4.638

Review 4.  Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.

Authors:  Fatemeh Farjadian; Amir Ghasemi; Omid Gohari; Amir Roointan; Mahdi Karimi; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2018-11-19       Impact factor: 5.307

5.  Photodynamic therapy for choroidal neovascularization in young adult patients.

Authors:  Rita Ehrlich; Michal Kramer; Irit Rosenblatt; Dov Weinberger; Karin Mimouni; Ethan Priel; Ruth Axer-Siegel
Journal:  Int Ophthalmol       Date:  2010-02-02       Impact factor: 2.031

6.  Inflammatory choroidal neovascularization.

Authors:  Piergiorgi Neri; Marta Lettieri; Cinzia Fortuna; Mara Manoni; Alfonso Giovannini
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

7.  Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis.

Authors:  Thi Ha Chau Tran; Christine Fardeau; Céline Terrada; Ghislaine Ducos De Lahitte; Bahram Bodaghi; Phuc Lehoang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-06       Impact factor: 3.117

8.  Self-assembled liposomal nanoparticles in photodynamic therapy.

Authors:  Magesh Sadasivam; Pinar Avci; Gaurav K Gupta; Shanmugamurthy Lakshmanan; Rakkiyappan Chandran; Ying-Ying Huang; Raj Kumar; Michael R Hamblin
Journal:  Eur J Nanomed       Date:  2013-07

Review 9.  Shining light on nanotechnology to help repair and regeneration.

Authors:  Asheesh Gupta; Pinar Avci; Magesh Sadasivam; Rakkiyappan Chandran; Nivaldo Parizotto; Daniela Vecchio; Wanessa C M A de Melo; Tianhong Dai; Long Y Chiang; Michael R Hamblin
Journal:  Biotechnol Adv       Date:  2012-08-21       Impact factor: 14.227

Review 10.  Verteporfin PDT for non-standard indications--a review of current literature.

Authors:  Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.